熱門資訊> 正文
Guardant Health在专利判决中败诉;被勒令支付2.45亿美元
2026-08-25 04:14
- A Delaware federal court issued final judgment in favor of TwinStrand BioSciences and the University of Washington, who accused Guardant Health (GH) of infringing two core patents related to TwinStrand's Duplex Sequencing technology.
- The court upheld a jury's $83.4M award for damages for infringement through June 30, 2023. It also awarded $19.5M in supplemental damages for sales between July 1, 2023, and Feb. 5, 2024, and $119.4M in accrued royalties at a 6% rate for sales between Feb. 5, 2024, and May 31, 2026.
- Another $22.9M was added for pre-judgment and post-judgment interest.
- Guardant Health will have to pay a 6% royalty on sales of covered products and services from June 1, 2026 through the patents' expiration on March 15, 2033.
- The company said it will appeal the final judgment, adding that its Reveal, Shield tests are not included in the order.
More on Guardant Health
- Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
- Guardant Health: Screening And MRD Are Just Getting Started
- Guardant Health, Inc. 2026 Q2 - Results - Earnings Call Presentation
- Guardant Health hits 52-week high after guidance hike
- Guardant Health Non-GAAP EPS of -$0.42 misses by $0.03, revenue of $335M beats by $20.57M
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。